Coherent Biopharma announced today that its investigational drug CBP-1019 has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration for treating recurrent endometrial cancer in patients who have undergone at least one line of platinum-based systemic therapy.
This milestone marks the second Fast Track Designation for Coherent Biopharma, following their previous designation for CBP-1008 in October 2024 for platinum-resistant ovarian clear cell carcinoma treatment.
Promising Clinical Results
The CBP-1019-101 global trial, conducted across centers in the U.S. and China, has shown encouraging early results. Among 61 patients with advanced solid tumors treated with various doses of CBP-1019, the drug demonstrated a favorable safety and tolerability profile. Notably, the treatment avoided common adverse events typically associated with topoisomerase I inhibitor-based antibody-drug conjugates, such as interstitial lung disease, stomatitis, and ocular toxicity.
In the endometrial cancer cohort, the results were particularly impressive. At the potential recommended Phase II dose of 3.0 mg/kg, administered intravenously every two weeks, the drug achieved:
- 42.9% objective response rate
- 100% disease control rate
- Median duration of response and progression-free survival not yet reached
- All patients continuing treatment at data cutoff
Innovative Drug Design
CBP-1019 represents a novel approach in cancer treatment as a bi-specific ligand drug conjugate. The drug employs Coherent's proprietary Bi-XDC technology platform to target two key receptors:
- Folate Receptor (FRα)
- Transient Receptor Potential Vanilloid Subfamily Member 6 receptor (TRPV6)
These receptors are frequently overexpressed in various cancers, including gynecological and GI malignancies. The drug carries a DX-8951 derivative, functioning as a topoisomerase I inhibitor.
Addressing Critical Unmet Needs
Endometrial cancer presents a significant health challenge, particularly in its advanced stages. Approximately 15% of patients are diagnosed with advanced disease, facing a mere 17% five-year survival rate. Current treatment options remain limited, highlighting the urgent need for new therapeutic approaches.
"This Fast Track Designation further underscores our platform's therapeutic potential and highlights the company's robust innovation capabilities in drug development," stated Dr. Robert Huang, Founder and CEO of Coherent. "We are committed to offering new therapeutic options for patients with advanced/metastatic EC worldwide."
Clinical Development Path
The Fast Track Designation will facilitate accelerated development and review of CBP-1019, potentially expediting its path to patients. This designation enables:
- Early and frequent communication with the FDA
- Potential eligibility for Accelerated Approval
- Possibility of Priority Review if relevant criteria are met
